close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Affimed N.V. - Common Stock (NQ:AFMD)

0.1815 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Affimed N.V. - Common Stock

< Previous 1 2 3 Next >
News headline image
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Reports 2022 Financial Results and Operational Progress
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for
From Affimed N.V.
Via GlobeNewswire
News headline image
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
From Affimed N.V.
Via GlobeNewswire
News headline image
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed to Present at the 2022 Jefferies London Healthcare Conference
From Affimed N.V.
Via GlobeNewswire
News headline image
Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Affimed N.V.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today